alexa Abstract | CD34-Negative is Highly Associated with T (15;17), T (V; 11q23) and the NPM1-Mutation Subtypes in 343 Newly Diagnosed Patients with Acute Myeloid Leukemia
ISSN: 2167-7700

Chemotherapy: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Special Issue Article Open Access


Objective: Recent reports found that several cytogenetic or molecular subtypes of acute myeloid leukemia (AML) are associated with CD34-positive. However, the status of CD34-negative in AML needs to be explored. In this study, we aimed to explore the prevalence of the CD34-negative patients and its association with molecular genetics status in a large consecutive AML cohort. Methods: A group of 343 consecutive newly diagnosed AML patients was retrospectively analyzed in our center. CD34 expression was detected by flow cytometry and considered negative when it was expressed in less than 20% of the bone marrow blast cells. The karyotype was analyzed by the G-banding technique. Leukemic fusion genes and mutated genes were detected by PCR method. Results: CD34-negative was found in 143 (41.7%) of the 343 patients. According to FAB classification, the percentages of CD34-negative patients were higher in the M3 and M5 (100% and 70%, respectively) and lower in the M2 and M4 subtypes (30.3% and 21.2%, respectively). According to the WHO classification, the percentage of CD34-negative patients was higher in those with t(15; 17), t(v; 11q23), and the NPM1-mutation (100%, n=37; 100%, n=7; and 81.7%, n=71, respectively) and lower in those with t(8;21) and AML with MDS-related changes (8.6%, n=35 and 5.0%, n=20, respectively). The patients with t(15; 17), t(v; 11q23) and the NPM1-mutation consisted of 71.3% (102/143) of the CD34-negative population and 6.5% (13/200) of the CD34-positive population (p<0.0001). A CD34-negative phenotype was associated with risk subgroups according to cytogenetics alone and when combining cytogenetics and molecular analysis (p=0.025 and p<0.0001, respectively). The sensitivity, specificity, positivepredictive value and negative-predictive value of the CD34-negative to t (15;17), t (v; 11q23) and the NPM1-mutation were 88.7%, 82.0%, 71.3% and 93.5%, respectively. Conclusions: The prevalence of the CD34-negative patients is very common in newly diagnosed AML. CD34- negative is highly associated with t (15;17), t(v; 11q23) and the NPM1-mutation in AML patients, which provide the evidence about the association of immunophenotype and molecular genetics.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Hong-Hu Zhu, Yan-Rong Liu and Ya-Zhen Qin


Acute myeloid leukemia, CD34, t(15,17), NPM1-mutation, MLLrearrangement, cytogenetics, Molecular analysis, Acute myeloid leukemia, CD34, t(15, 17), NPM1-mutation, MLLrearrangement, cytogenetics, Molecular analysis

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version